Sollis Therapeutics Stock

sollistx.comBioTechFounded: 2017Funding to Date: $49.89MM

Sollis Therapeutics is a clinical-stage pharmaceutical company developing novel interventional non-steroid, non-opioid analgesics.

Register for Details

For more details on financing and valuation for Sollis Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Gregory Fiore MD
Co-Founder, Chief Executive Officer, President and Board Member
Bryan Jones JD
Chief Operating Officer & Co-Founder

Board Members

Andrew ElBardissi MD
Deerfield Management
Greg Licholai MD
Gregory Fiore MD
Kevin Wasserstein
Neurotechnology Innovations Translator
Richard Mott
Steven Hochberg

Other companies like Sollis Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$143.8MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$185MM
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$138.75MM
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$289.42MM
Sector
Last Round Est. Valuation
$1.08B